Tag: VAP

Upvote Story 6
Ventilator-associated pneumonia (VAP) remains a serious complication of mechanical ventilation (MV), and has an incidence between 2 and 16 episodes per 1000 ventilator-days, an attributable mortality of 5–13%, excess ICU length of stay (LOS) for survivors up to 9 days, and extra costs. Many studies have reported decreased VAP rates associated with the use of bundles of preventive measures. Fewer studies have reported compliance with... Read More | Comment
Upvote Story 6
Intensive care is an interesting specialty. From all the early excitement in the 1970s, passing through two decades of intensive physiological use at the bedside, intensive care landed on the rough ground of modern randomized controlled trials (RCTs) in the late 1990s and early 2000s. The increasing number of critically ill patients coupled with new monitoring devices and important funding both from governmental and private... Read More | Comment
Upvote Story 12
The published reductions in asynchrony and length of stay in the ICU with proportional assist ventilation (PAV ventilation by Medtronic) led to shorter time on ventilation, and reduced incidence of ventilator-associated pneumonia (VAP) and tracheostomy in this decision analytic model. Increased patient survival with PAV resulted in annual healthcare costs being accumulated over a longer period. This made it most likely that PAV is cost-saving... Read More | Comment
Upvote Story 8
Approximately 50 percent of all patients receiving mechanical ventilator support develop ventilator-associated pneumonia (VAP). Researchers at Massachusetts General Hospital (MGH) have developed an automated system for identifying patients at risk for complications associated with the use of mechanical ventilators. The new system uses an algorithm that has been shown to be 100 percent accurate in identifying at-risk patients when provided with necessary data, according to... Read More | Comment
Upvote Story 9
This large, prospective multi-centre study demonstrates that a national approach (incorporating a care bundle, education cascade, and clinical governance process) for Ventilator-associated pneumonia (VAP) prevention is feasible and can be successful. Furthermore, their results suggest that the longer such a bundle is implemented, the more successful it becomes. A national multi-modal approach to VAP prevention (including a care bundle, systematic education cascade, and clinical governance... Read More | Comment
Upvote Story 19
ICU is a hotbed of infections and measures are taken to prevent these infections. Ventilator associated pneumonia is one of the Intensive Care Unit related infections. This book tells us what ventilator associated pneumonia is, its possible bacterial etiological agents from a Microbiological point of view and the various measures which can be taken to manage ventilator associated pneumonia. Materials and methods to process and... Read More | Comment
Upvote Story 7
Because nonventilator hospital-acquired pneumonia (NV-HAP) is understudied, our purpose was to determine the incidence, overall burden, and level of documented pneumonia preventive interventions of NV-HAP in 24 U.S. hospitals. This multicenter, nationwide study highlights the significant burden of NV-HAP in the U.S. acute care hospital setting. We found that NV-HAP occurred on every hospital unit, including in younger, healthy patients. This indicates that although some... Read More | Comment
Upvote Story 5
This study assesses trends and risk factors of ventilator-associated pneumonia (VAP) according to age, particularly in the elderly admitted to French ICUs between 2007 and 2014. Ventilator-associated pneumonia incidence is lower but did not decrease over time in very old patients compared with young patients. Overall and multidrug-resistant organism–related ventilator-associated pneumonia incidence rates were expressed per 1,000 intubation days at risk. Age was stratified into... Read More | Comment
Upvote Story 6
Ceftazidime-avibactam was noninferior to meropenem for nosocomial pneumonia including ventilator-associated pneumonia (VAP) from gram-negative organisms, results from the REPROVE trial demonstrated. Nosocomial or hospital-acquired pneumonia is a common hospital-acquired infection associated with increased cost and mortality. Further, nosocomial pneumonia is associated with gram-negative pathogens such as Pseudomonas aeruginosa and Enterobacteriaceae that may carry extended-spectrum beta-lactamases and carbapenemase, thereby limiting the treatment options. Read More | Comment
Upvote Story 8
FDA has approved Allergan’s supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ® (ceftazidime and avibactam) to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older. This expanded use... Read More | Comment
Upvote Story 13
There is an association between ventilator-associated condition and infection-related ventilator-associated complication in critically ill children with acute kidney injury, ventilatory support, and neuromuscular blockade. Attention should be given by clinical practitioners to recognize these modifiable risk factors and to implement strategies to decrease the prevalence of ventilator-associated events. We applied the definition for ventilator-associated condition (i.e., a sustained increase in ventilator settings after a period... Read More | Comment
Upvote Story 11
BALF IL-1β and IL-8 are amongst the strongest markers yet identified for accurately demarcating VAP within the larger population of patients with suspected VAP. These findings have potential implications for reduction in unnecessary antibiotic use but require further validation in larger populations. Seventy-two patients had recoverable lavage—24% had VAP. BALF interleukin-1β (IL-1β), IL-8, granulocyte colony-stimulating factor and macrophage inflammatory protein-1α were significantly higher in the... Read More | Comment
Upvote Story 5
Lung ultrasound (LUS) is an accurate tool to diagnose community-acquired pneumonia. However, it is not yet an established tool to diagnose ventilator-associated pneumonia (VAP). Small subpleural consolidations and dynamic air bronchograms were the most useful sonographic signs to diagnose VAP in suspected patients. Clinical scores including LUS had better diagnosis accuracy than LUS alone. There are no data on LUS for VAP screening. Read More | Comment
Upvote Story 8
This real-life study emphasizes oseltamivir efficacy on in-hospital outcome when administrated within 2 days of the onset of symptoms. Even if physicians’ awareness of the influenza disease has been undeniably enhanced since the last pandemic, many efforts are still required to improve influenza-infected patient management in ICUs, including early oseltamivir administration. Read More | Comment
Upvote Story 5
Critical illness is characterized by a loss of commensal flora and an overgrowth of potentially pathogenic bacteria, leading to a high susceptibility to nosocomial infections. Probiotics are living non-pathogenic microorganisms, which may protect the gut barrier, attenuate pathogen overgrowth, decrease bacterial translocation and prevent infection. The purpose of this updated systematic review is to evaluate the overall efficacy of probiotics and synbiotic mixtures on clinical... Read More | Comment
Upvote Story 10
We read with great interest the study performed by Paula Ramirez and colleagues. The study included 71 patients with ventilator-associated pneumonia (VAP) and the authors coined a new term called "gradual VAP". The result of this study indicated that an early antibiotic treatment for patients with gradual VAP was associated with an increased rate of early clinical response. Based on the results of previous studies... Read More | Comment
Upvote Story 14
Clinical failures in ventilator-associated pneumonia (VAP) caused by gram-negative bacteria are common and associated with substantial morbidity, mortality, and resource utilization. In this trial of adjunctive aerosol therapy compared with standard of care IV antibiotics in patients with gram-negative VAP, the AFIS was ineffective in improving clinical outcomes despite reducing bacterial burden. Read More | Comment
Upvote Story 4
Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections which increase mortality rate and length stay of hospitalization. Oral care would not only improve patient’s oral health and well-being, but it can also reduce the incidence rate of ventilator-associated pneumonia. This clinical trial recruited 100 participants who were randomly assigned to a control group (receiving oral care by nurses) and an intervention group... Read More | Comment
Upvote Story 7
Many patients started on antibiotics for possible ventilator-associated pneumonia (VAP) do not have pneumonia. Patients with minimal and stable ventilator settings may be suitable candidates for early antibiotic discontinuation. Very short antibiotic courses (1–3 days) were associated with outcomes similar to longer courses (>3 days) in patients with suspected VAP but minimal and stable ventilator settings. Assessing serial ventilator settings may help clinicians identify candidates... Read More | Comment